Aug 2026· Cancer Science· 0 citations· 33 references
Medicine
TL;DR
A previously unrecognized TRIM59–PTRF–AKT/c‐Myc axis that drives BLCA progression is defined and TRIM59 is highlighted as a potential prognostic biomarker and therapeutic target.
Abstract
ABSTRACT Tripartite motif‐containing 59 (TRIM59) is an E3 ubiquitin ligase implicated in multiple malignancies, but its role in bladder cancer (BLCA) remains incompletely understood. In this study, we identified TRIM59 as a clinically relevant oncogenic driver in BLCA through integrated transcriptomic, clinical, and functional analyses. TRIM59 was significantly upregulated in BLCA tissues and cell lines, and high TRIM59 expression was associated with advanced stage, higher grade, recurrence, and poor prognosis. Functionally, TRIM59 promoted BLCA proliferation, cell‐cycle progression, migration, invasion, and metastatic colonization in vitro and in vivo. Mechanistically, TRIM59 directly interacted with PTRF/Cavin‐1 and induced its RING domain‐dependent K48‐linked polyubiquitination and proteasomal degradation. Additional mutagenesis analyses identified K98, K122, K152, and K317 as major ubiquitination sites on PTRF. In contrast to the oncogenic role of TRIM59, PTRF was downregulated in BLCA and exhibited tumor‐suppressive properties. PTRF restoration attenuated TRIM59‐driven proliferation, invasion, and epithelial‐mesenchymal transition, whereas PTRF depletion partially rescued the inhibitory effects of TRIM59 silencing. Further analyses showed that PTRF restrains AKT phosphorylation and suppresses MYC transcriptional activity, thereby limiting c‐Myc‐driven proliferative signaling. Collectively, these findings define a previously unrecognized TRIM59–PTRF–AKT/c‐Myc axis that drives BLCA progression and highlight TRIM59 as a potential prognostic biomarker and therapeutic target.
Lung adenocarcinoma (LUAD) is one of the major subtypes of non-small cell lung cancer (NSCLC), but the molecular mechanisms underlying LUAD initiation and progression remain incompletely understood. In the present study, we identified TRIM46 as a key driver of LUAD progression. TRIM46 is significantly overexpressed i...
Shao-Kun Yu, Xiao Ke, Zhi-Li Liu et al.· Cell Death & Disease· 0 citations
Replication factor C subunit 4 (RFC4) dysregulation has been implicated in tumor progression and poor prognosis across multiple cancer types. Triple‐negative breast cancer (TNBC) is an aggressive subtype with limited treatment options and poor outcomes, underscoring the need for effective therapeutic targets. However,...
Cheng Guo, Li Liu, Li-Xiang Sun et al.· MedComm· 0 citations
Tripartite motif 29 (TRIM29) is a member of the subfamily of the E3 ubiquitin ligases and regulates several cellular processes in cancer. However, the role of TRIM29 in hepatocellular carcinoma (HCC) and the underlying mechanism remain undetermined. In this study, we discovered that TRIM29 was upregulated in human HC...
Yi Guo, Jin-Dong Yuan, Chu-Jiao Hu et al.· Cell Death Discovery· 0 citations
ABSTRACT Lung adenocarcinoma (LUAD) remains a leading cause of cancer‐related mortality. Integrative multi‐omics and machine‐learning analyses across independent cohorts identified CYYR1 as a frequently downregulated transmembrane protein in LUAD, with low expression associated with poor prognosis and promoter hypermet...
Feng-Sheng Dai, Jing-Yi Tang, Huan Rong et al.· Advancement of science· 0 citations
TRIM22 is a TRIM family E3 ubiquitin ligase whose expression is strongly induced by interferons. For many years, it has been identified primarily as an antiviral effector, a role that remains well validated. A growing body of cancer-related work now forces us to expand that view considerably. Depending on tumor type, u...
Chen-Jie Qiu, Liang-Liang Dai· Frontiers in Cell and Develo...· 0 citations
It is demonstrated that the TUBB4B inhibitor, mebendazole, effectively suppresses the enhanced proliferation in lower‐expression PNLDC1 models, positioning it as a promising therapeutic agent.